ELCC 2017: Industry Participation

The European Lung Cancer Conference 2017 (ELCC 2017), is the most important conference in Europe for all clinical practitioners involved in the diagnostic work-up and treatment of lung cancer and other thoracic malignancies.

It brings together a unique community of medical professionals to facilitate the advancement of a personalised approach to the management of lung and other thoracic cancers and the implementation of new discoveries into clinical practice.

Fast facts: ELCC 2017

  • Expecting over 2200 international participants
  • Specialists and Key Opinion Leaders (KOLs) from all over the world in one place and as one community
  • 16 educational and 4 key note lectures sessions running over four days
  • An internationally renowned faculty
  • 9 Industry Satellite Symposia
  • Vibrant commercial exhibition
  • Excellent networking opportunities

Past attendance

ESMO gratefully acknowledges the valuable contribution of the following organisations in the ELCC Conferences over the years.

  • Abbott Laboratories
  • AbbVie
  • Agennix
  • Amgen
  • Ariad Pharmaceuticals
  • Astrazeneca
  • Bayer Schering Pharma
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Clovis Oncology
  • Cis Bio International
  • Daiichi Sankyo Europe
  • Eli Lilly
  • Elsevier
  • GE Healthcare
  • GSK
  • Helsinn Healthcare
  • Karl Storz
  • Merck Serono
  • Microsulis Medical Ltd.
  • MSD
  • Novartis Oncology
  • Olympus Medical Systems Europe
  • Otsuka Pharmaceuticals
  • Pfizer Oncology
  • Qiagen
  • Roche
  • Rosetta Genomics
  • Sanofi
  • Varian Medical Systems
  • Wisepress Ltd

How can I participate in ELCC 2017?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our conferences.

Contact the ESMO Events Sponsorship Team for more details. We look forward to hearing from you!